These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 11816163)

  • 1. The HIV vaccine pipeline, from preclinical to phase III.
    Schultz AM; Bradac JA
    AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel vaccine delivery systems: solutions to HIV vaccine dilemmas?
    Sutter G; Haas J
    AIDS; 2001; 15 Suppl 5():S139-45. PubMed ID: 11816162
    [No Abstract]   [Full Text] [Related]  

  • 3. [Development of a vaccine against HIV: is this aim accomplishable?].
    Wagner R; Asbach B
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():36-9. PubMed ID: 23961653
    [No Abstract]   [Full Text] [Related]  

  • 4. Tiny steps towards an HIV vaccine.
    Willyard C
    Nature; 2010 Jul; 466(7304):S8. PubMed ID: 20631706
    [No Abstract]   [Full Text] [Related]  

  • 5. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees.
    Lockey TD; Slobod KS; Caver TE; D'Costa S; Owens RJ; McClure HM; Compans RW; Hurwitz JL
    Immunol Res; 2000; 21(1):7-21. PubMed ID: 10803879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thailand's Prime-Boost HIV Vaccine Phase III.
    Trinvuthipong C
    Science; 2004 Feb; 303(5660):954-5. PubMed ID: 14963308
    [No Abstract]   [Full Text] [Related]  

  • 7. [Prospects for vaccine development against HIV infection].
    Kurth R; Binninger D; Ennen J; Denner J; Hartung S; Norley S
    Verh Dtsch Ges Inn Med; 1991; 97():394-402. PubMed ID: 1808921
    [No Abstract]   [Full Text] [Related]  

  • 8. Poxvirus vector-based HIV vaccines.
    Pantaleo G; Esteban M; Jacobs B; Tartaglia J
    Curr Opin HIV AIDS; 2010 Sep; 5(5):391-6. PubMed ID: 20978379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of replication-competent viral vectors for HIV vaccine delivery.
    Parks CL; Picker LJ; King CR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):402-11. PubMed ID: 23925000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progress in the development of an HIV-1 vaccine.
    Letvin NL
    Science; 1998 Jun; 280(5371):1875-80. PubMed ID: 9632379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Public health. A sound rationale needed for phase III HIV-1 vaccine trials.
    Burton DR; Desrosiers RC; Doms RW; Feinberg MB; Gallo RC; Hahn B; Hoxie JA; Hunter E; Korber B; Landay A; Lederman MM; Lieberman J; McCune JM; Moore JP; Nathanson N; Picker L; Richman D; Rinaldo C; Stevenson M; Watkins DI; Wolinsky SM; Zack JA
    Science; 2004 Jan; 303(5656):316. PubMed ID: 14726576
    [No Abstract]   [Full Text] [Related]  

  • 13. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review.
    Girard MP; Osmanov S; Assossou OM; Kieny MP
    Vaccine; 2011 Aug; 29(37):6191-218. PubMed ID: 21718747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 clinical trials of the National Institutes of Health Vaccine Research Center HIV/AIDS candidate vaccines.
    Robinson HL; Weinhold KJ
    J Infect Dis; 2006 Dec; 194(12):1625-7. PubMed ID: 17109331
    [No Abstract]   [Full Text] [Related]  

  • 15. Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women.
    Gilbert PB; Excler JL; Tomaras GD; Carpp LN; Haynes BF; Liao HX; Montefiori DC; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Kaewkungwal J; Kijak GH; Tovanabutra S; Francis DP; Lee C; Sinangil F; Berman PW; Premsri N; Kunasol P; O'Connell RJ; Michael NL; Robb ML; Morrow R; Corey L; Kim JH
    PLoS One; 2017; 12(5):e0176428. PubMed ID: 28493891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy rebuttal. HIV vaccine trial justified.
    McNeil JG; Johnston MI; Birx DL; Tramont EC
    Science; 2004 Feb; 303(5660):961. PubMed ID: 14963313
    [No Abstract]   [Full Text] [Related]  

  • 17. M cell DNA vaccination for CTL immunity to HIV.
    Wang X; Hone DM; Haddad A; Shata MT; Pascual DW
    J Immunol; 2003 Nov; 171(9):4717-25. PubMed ID: 14568947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress toward an HIV vaccine.
    Letvin NL
    Annu Rev Med; 2005; 56():213-23. PubMed ID: 15660510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.
    Hinkula J
    Expert Rev Vaccines; 2007 Apr; 6(2):203-12. PubMed ID: 17408370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunisation with gp160 in HIV-1 infection.
    Pontesilli O; Aiuti F
    Lancet; 1999 Sep; 354(9182):948-9. PubMed ID: 10489977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.